Drug details

Qinlock (ripretinib tablets)

type of PDGFR-alpha Inhibitors

Qinlock (ripretinib) is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• constipation,
• fatigue,
• abdominal pain,
• hair loss,
• muscle pain,
• decreased appetite,
• decreased phosphate
• hand-foot syndrome (palmar¬plantar erythrodysesthesia),
• increased lipase, and

The following drugs are related to Qinlock, either as a replacement or used together:

• Cyramza (ramucirumab solution for intravenous infusion)
• Taxotere (docetaxel for injection)
• Herceptin (trastuzumab)
• Keytruda (pembrolizumab for injection)
• Mutamycin (mitomycin)